Jump to content

EMR1: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
Line 8: Line 8:
Utilizing F4/80 knockout mice, Lin et al. showed that F4/80 is not necessary for the development of tissue macrophages but is required for the induction of efferent CD8<sup>+</sup> regulatory T cells needed for peripheral tolerance.<ref>{{vcite2 journal | vauthors = Lin HH, Faunce DE, Stacey M, Terajewicz A, Nakamura T, Zhang-Hoover J, Kerley M, Mucenski ML, Gordon S, Stein-Streilein J | title = The macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral tolerance | journal = The Journal of Experimental Medicine | volume = 201 | issue = 10 | pages = 1615–25 | date = May 2005 | pmid = 15883173 | doi = 10.1084/jem.20042307 }}</ref>
Utilizing F4/80 knockout mice, Lin et al. showed that F4/80 is not necessary for the development of tissue macrophages but is required for the induction of efferent CD8<sup>+</sup> regulatory T cells needed for peripheral tolerance.<ref>{{vcite2 journal | vauthors = Lin HH, Faunce DE, Stacey M, Terajewicz A, Nakamura T, Zhang-Hoover J, Kerley M, Mucenski ML, Gordon S, Stein-Streilein J | title = The macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral tolerance | journal = The Journal of Experimental Medicine | volume = 201 | issue = 10 | pages = 1615–25 | date = May 2005 | pmid = 15883173 | doi = 10.1084/jem.20042307 }}</ref>


== Pathology ==
== Clinical significance ==
Legrand et al. recently demonstrated that EMR1 can serve as a therapeutic target for depletion of these cells in eosinophilic disorders by using afucosylated antibodies.<ref>{{vcite2 journal | vauthors = Legrand F, Tomasevic N, Simakova O, Lee CC, Wang Z, Raffeld M, Makiya MA, Palath V, Leung J, Baer M, Yarranton G, Maric I, Bebbington C, Klion AD | title = The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders | journal = The Journal of Allergy and Clinical Immunology | volume = 133 | issue = 5 | pages = 1439–47, 1447.e1-8 | date = May 2014 | pmid = 24530099 | doi = 10.1016/j.jaci.2013.11.041 }}</ref>
Legrand et al. recently demonstrated that EMR1 can serve as a therapeutic target for depletion of these cells in eosinophilic disorders by using afucosylated antibodies.<ref>{{vcite2 journal | vauthors = Legrand F, Tomasevic N, Simakova O, Lee CC, Wang Z, Raffeld M, Makiya MA, Palath V, Leung J, Baer M, Yarranton G, Maric I, Bebbington C, Klion AD | title = The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders | journal = The Journal of Allergy and Clinical Immunology | volume = 133 | issue = 5 | pages = 1439–47, 1447.e1-8 | date = May 2014 | pmid = 24530099 | doi = 10.1016/j.jaci.2013.11.041 }}</ref>


Revision as of 15:51, 21 April 2015

Template:PBB EGF-like module-containing mucin-like hormone receptor-like 1 also known as F4/80 is a protein encoded by the ADGRE1 gene.[1][2][3][4][5] EMR1 is a member of the adhesion-GPCR family.[6][7] Adhesion-GPCRs are characterized by an extended extracellular region often possessing N-terminal protein modules that is linked to a TM7 region via a domain known as the GPCR-Autoproteolysis INducing (GAIN) domain.[8]

EMR1 expression in human is restricted to eosinophils and is a specific marker for these cells.[9] Interestingly, the murine homolog of EMR1, F4/80 is a well-known and widely-used marker of murine macrophage populations.[10] The N-terminal fragment (NTF) of EMR1 contains 4-6 Epidermal Growth Factor-like (EGF-like) domains in human and 4-7 EGF-like domains in the mouse.[11]

Function

Utilizing F4/80 knockout mice, Lin et al. showed that F4/80 is not necessary for the development of tissue macrophages but is required for the induction of efferent CD8+ regulatory T cells needed for peripheral tolerance.[12]

Clinical significance

Legrand et al. recently demonstrated that EMR1 can serve as a therapeutic target for depletion of these cells in eosinophilic disorders by using afucosylated antibodies.[13]

See also

References

  1. ^ Baud V, Chissoe SL, Viegas-Péquignot E, Diriong S, N'Guyen VC, Roe BA, Lipinski M (Mar 1995). "EMR1, an unusual member in the family of hormone receptors with seven transmembrane segments". Genomics. 26 (2): 334–44. doi:10.1016/0888-7543(95)80218-B. PMID 7601460.
  2. ^ McKnight AJ, Gordon S (Mar 1998). "The EGF-TM7 family: unusual structures at the leukocyte surface". Journal of Leukocyte Biology. 63 (3): 271–80. PMID 9500513.
  3. ^ "Entrez Gene: EMR1 egf-like module containing, mucin-like, hormone receptor-like 1".
  4. ^ Leenen PJ, de Bruijn MF, Voerman JS, Campbell PA, van Ewijk W (Sep 1994). "Markers of mouse macrophage development detected by monoclonal antibodies". Journal of Immunological Methods. 174 (1–2): 5–19. doi:10.1016/0022-1759(94)90005-1. PMID 8083537.
  5. ^ Hamann, J; Aust, G; Araç, D; Engel, FB; Formstone, C; Fredriksson, R; Hall, RA; Harty, BL; Kirchhoff, C; Knapp, B; Krishnan, A; Liebscher, I; Lin, HH; Martinelli, DC; Monk, KR; Peeters, MC; Piao, X; Prömel, S; Schöneberg, T; Schwartz, TW; Singer, K; Stacey, M; Ushkaryov, YA; Vallon, M; Wolfrum, U; Wright, MW; Xu, L; Langenhan, T; Schiöth, HB (April 2015). "International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors". Pharmacological reviews. 67 (2): 338–67. PMID 25713288.
  6. ^ Stacey M, Yona S (2011). Adhesion-GPCRs: Structure to Function (Advances in Experimental Medicine and Biology). Berlin: Springer. ISBN 1-4419-7912-3.
  7. ^ Langenhan, T; Aust, G; Hamann, J (21 May 2013). "Sticky signaling--adhesion class G protein-coupled receptors take the stage". Science signaling. 6 (276): re3. PMID 23695165.
  8. ^ Araç D, Boucard AA, Bolliger MF, Nguyen J, Soltis SM, Südhof TC, Brunger AT (Mar 2012). "A novel evolutionarily conserved domain of cell-adhesion GPCRs mediates autoproteolysis". The EMBO Journal. 31 (6): 1364–78. doi:10.1038/emboj.2012.26. PMC 3321182. PMID 22333914.
  9. ^ Hamann J, Koning N, Pouwels W, Ulfman LH, van Eijk M, Stacey M, Lin HH, Gordon S, Kwakkenbos MJ (Oct 2007). "EMR1, the human homolog of F4/80, is an eosinophil-specific receptor". European Journal of Immunology. 37 (10): 2797–802. doi:10.1002/eji.200737553. PMID 17823986.
  10. ^ Austyn JM, Gordon S (Oct 1981). "F4/80, a monoclonal antibody directed specifically against the mouse macrophage". European Journal of Immunology. 11 (10): 805–15. doi:10.1002/eji.1830111013. PMID 7308288.
  11. ^ Gordon S, Hamann J, Lin HH, Stacey M (Sep 2011). "F4/80 and the related adhesion-GPCRs". European Journal of Immunology. 41 (9): 2472–6. doi:10.1002/eji.201141715. PMID 21952799.
  12. ^ Lin HH, Faunce DE, Stacey M, Terajewicz A, Nakamura T, Zhang-Hoover J, Kerley M, Mucenski ML, Gordon S, Stein-Streilein J (May 2005). "The macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral tolerance". The Journal of Experimental Medicine. 201 (10): 1615–25. doi:10.1084/jem.20042307. PMID 15883173.
  13. ^ Legrand F, Tomasevic N, Simakova O, Lee CC, Wang Z, Raffeld M, Makiya MA, Palath V, Leung J, Baer M, Yarranton G, Maric I, Bebbington C, Klion AD (May 2014). "The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders". The Journal of Allergy and Clinical Immunology. 133 (5): 1439–47, 1447.e1-8. doi:10.1016/j.jaci.2013.11.041. PMID 24530099.
Retrieved from "https://en.wikipedia.org/w/index.php?title=EMR1&oldid=657600060"